JAB-3068 is theF second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).

JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.

JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have shown that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.